Back to News
Market Impact: 0.3
MIRA Pharmaceuticals, Inc. Announces Positive Results from 21-day Preclinical Study of MIRA-55
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
MIRA Pharmaceuticals reported positive results from a 21-day IND-enabling preclinical proof-of-concept study of MIRA-55 in a validated model of chronic inflammatory pain. Once-daily oral dosing significantly reduced mechanical pain measures; the provided article text is truncated before the remaining results are specified.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
MIRA0.70
More News
- SK Hynix shares slide after chipmaker scraps Solidigm IPO plans
- Apple’s iPhone Duo Hits Stores in Face of Short Supply and High Demand
- OpenAI nears up to $30 billion funding round at $1.25 trillion valuation led by UAE investors
- Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
- Moderna shares plunge after leak of partial cancer vaccine data
- SpaceX records $561 million investment gain from stake in Elon Musk's Boring Co.
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AllMind's Data Standardization Methodology: Our Approach to Fundamentals
- What Makes Financial Data Ready for AI Research?